BRPI0415113A - compostos de lactama condensados - Google Patents
compostos de lactama condensadosInfo
- Publication number
- BRPI0415113A BRPI0415113A BRPI0415113-5A BRPI0415113A BRPI0415113A BR PI0415113 A BRPI0415113 A BR PI0415113A BR PI0415113 A BRPI0415113 A BR PI0415113A BR PI0415113 A BRPI0415113 A BR PI0415113A
- Authority
- BR
- Brazil
- Prior art keywords
- group
- compound
- disease
- compounds
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"COMPOSTOS DE LACTAMA CONDENSADOS". Esta invenção proporciona um composto da fórmula (I): em que R¬ 1¬ representa um grupo arila tendo de 6 a 10 átomos de carbono em anel etc.; R¬ 2¬ representa um átomo de hidrogênio, etc., n representa 0, 1 ou 2; o referido grupo heteroarila é não substituído ou substituído e o referida arila é substituída por pelo menos um substituinte selecionado do grupo constituída por substituintes <244>; os referidos substituintes <244> são selecionados do grupo constituído por átomos de halogênio, grupos alquila tendo desde 1 a 6 átomos de carbono, etc.; ou um éster farmaceuticamente aceitável de tal composto, ou um seu sal farmaceuticamente aceitável. Estes compostos são úteis para o tratamento de condições de doença causadas por sobreativa do receptor NR2B de NMDA tal como dor, acidente vascular cerebral, lesão cerebral traumática, mal de Parkinson, mal de Alzheimer, depressão, ansiedade, enxaqueca ou semelhantes, num mamífero, especialmente seres humanos. Esta invenção também proporciona uma composição farmacêutica compreendendo o composto acima.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50967003P | 2003-10-08 | 2003-10-08 | |
PCT/IB2004/003125 WO2005035523A1 (en) | 2003-10-08 | 2004-09-27 | Fused lactam compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0415113A true BRPI0415113A (pt) | 2006-11-28 |
Family
ID=34435007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0415113-5A BRPI0415113A (pt) | 2003-10-08 | 2004-09-27 | compostos de lactama condensados |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1673367A1 (pt) |
JP (1) | JP2007508288A (pt) |
BR (1) | BRPI0415113A (pt) |
CA (1) | CA2541162A1 (pt) |
MX (1) | MXPA06003748A (pt) |
WO (1) | WO2005035523A1 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070185168A1 (en) * | 2004-04-07 | 2007-08-09 | Takai Haruki S | Piperidine derivatives |
CN103002893B (zh) | 2010-07-30 | 2017-05-10 | 东丽株式会社 | 神经障碍性疼痛的治疗药或预防药 |
JP6042968B2 (ja) | 2012-04-20 | 2016-12-14 | ユセベ ファルマ ソシエテ アノニム | パーキンソン病の処置方法 |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神***病を処置するための方法および組成物 |
CA2904767C (en) | 2013-03-15 | 2022-06-21 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
US9187506B2 (en) * | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
US9221796B2 (en) | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
CN107810002B (zh) | 2015-05-22 | 2021-01-05 | 艾吉因生物股份有限公司 | 左乙拉西坦的延时释放药物组合物 |
KR20180064507A (ko) | 2015-10-14 | 2018-06-14 | 브리스톨-마이어스 스큅 컴퍼니 | 선택적 nr2b 길항제 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2146578T3 (es) * | 1990-05-10 | 2000-08-16 | Pfizer | Indolona neuroprotectora y derivados relacionados. |
RU2065859C1 (ru) * | 1991-07-17 | 1996-08-27 | Пфайзер Инк. | Производные 2-(4-гидроксипиперидино)-1-алканола и производные 2-(4-гидроксипиперидино)-1-алканона |
FR2688504B1 (fr) * | 1992-03-13 | 1995-05-05 | Synthelabo | Derives de 2-(piperidin-1-yl)ethanol, leur preparation et leur application en therapeutique. |
DE69309297T2 (de) * | 1992-10-30 | 1997-07-03 | Pfizer | Neuroprotektive 3,4-dihydro-2(1h)-chinolone |
US5498610A (en) * | 1992-11-06 | 1996-03-12 | Pfizer Inc. | Neuroprotective indolone and related derivatives |
US6713490B2 (en) * | 2002-04-26 | 2004-03-30 | Pfizer, Inc. | 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists |
-
2004
- 2004-09-27 WO PCT/IB2004/003125 patent/WO2005035523A1/en not_active Application Discontinuation
- 2004-09-27 EP EP04769480A patent/EP1673367A1/en not_active Withdrawn
- 2004-09-27 BR BRPI0415113-5A patent/BRPI0415113A/pt not_active IP Right Cessation
- 2004-09-27 JP JP2006530731A patent/JP2007508288A/ja not_active Withdrawn
- 2004-09-27 CA CA002541162A patent/CA2541162A1/en not_active Abandoned
- 2004-09-27 MX MXPA06003748A patent/MXPA06003748A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA2541162A1 (en) | 2005-04-21 |
WO2005035523A1 (en) | 2005-04-21 |
JP2007508288A (ja) | 2007-04-05 |
EP1673367A1 (en) | 2006-06-28 |
MXPA06003748A (es) | 2006-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0510666A (pt) | compostos de amida de arila ou heteroarila de metila substituìda, composições farmacêuticas compreendendo os mesmos, uso e combinação | |
BRPI0409241A (pt) | compostos bicìclicos como antagonistas do receptor de nr2b, composições farmacêuticas compreendendo os mesmos e seu uso | |
MXPA06011194A (es) | Tiadiazolidinonas como inhibidores de gsk-3. | |
BRPI0414514A (pt) | uso de um composto, composto, e, composições farmacêuticas | |
EA200301216A1 (ru) | Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания | |
AR036596A1 (es) | Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonista de cb1 | |
BRPI0509377A (pt) | compostos de ácido alfa arila ou heteroaril metil beta piperidino propanóico como antagonistas do receptor orl1 | |
BRPI0414130B8 (pt) | compostos de fenilamida ou piridilamida, seu uso e composições farmacêuticas que os compreendem. | |
BRPI0615111B8 (pt) | composto, composição farmacêutica, e, uso do composto | |
BRPI0616574A2 (pt) | derivado de sulfonamida tendo atividade antagonìstica de receptor de pgd2 | |
BRPI0610030B8 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
BRPI0517740A (pt) | compostos n-sulfonilaminobenzil-2fenóxi acetamida substituìda | |
BR0014137A (pt) | Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
BR0311541A (pt) | indol, azaindol e 4-aquenil piperidina amidas heterocìclicas relacionadas | |
HUP0401889A2 (hu) | 1,8-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények | |
BRPI0409042A (pt) | derivados de 4-pirimidona-2,3,6-tri-substituìdos | |
BR0306208A (pt) | Compostos de dibenzilamina e seu uso farmacêutico | |
BRPI0408591A (pt) | derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda | |
EA200200716A1 (ru) | Арилконденсированные азаполициклические соединения | |
BRPI0512916A (pt) | derivado de tienopirazol tendo atividade inibidora de pde 7 | |
EA200500006A1 (ru) | Лекарственное средство для лечения нейродегенеративных заболеваний | |
BRPI0415113A (pt) | compostos de lactama condensados | |
BRPI0408605A (pt) | derivados de 8-perfluoralquil-6,7,8,9-tetrahidropirimido[1,2-a]piri midin-4-ona substituìdos | |
AR040928A1 (es) | Compuestos de acidos sulfona-hidroxamicos aromaticos, composiciones farmaceuticas y su uso en la preparacion de medicamentos utiles como inhibidores de proteasas | |
BRPI0415109A (pt) | compostos de 1-[2-(4-hidroxifenil)-2-hidroxietil]-piperidin-4-ol como antagonistas de receptor de nmda |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |